Get the latest Science News and Discoveries

Eight-year ADAURA update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated NSCLC

None

Related news:

Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC

Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC

Zidesamtinib demonstrates 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC